Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A
Department of Urology, Section Pediatric Urology, Alexandria University, 21 Amin Fikery, Ramleh Station, Alexandria, Egypt.
J Urol. 2006 Oct;176(4 Pt 2):1767-70; discussion 1770. doi: 10.1016/j.juro.2006.03.119.
We evaluated botulinum-A toxin (Botox) injection into the urethral urinary sphincter in children with nonneurogenic neurogenic bladder to decrease urethral resistance and improve voiding. In these patients alpha-blocker medications had failed and injection was an alternative to unavailable biofeedback.
Prospective treatment was performed in 10 children 6 to 17 years old (mean age 8) with nonneurogenic neurogenic bladder using botulinum-A toxin (Botox). Preoperatively all children were evaluated by ultrasound, voiding cystourethrography, excretory urography, magnetic resonance imaging and urodynamic studies, including pressure flow, electromyography and uroflowmetry. One patient had unilateral G3 reflux and 4 had bilateral G1 to G3 hydronephrosis. Using a rigid pediatric endoscope and a 4Fr injection needle 50 to 100 IU botulinum-A toxin were injected into the external sphincter at the 3, 6 and 9 o'clock positions. Followup was 6 to 15 months. Repeat injections every month were given according to the response with a maximum of 3 injections.
Immediately after botulinum-A toxin injection all except 1 patient were able to void without catheterization. No acute complications occurred. Four patients with bilateral hydronephrosis and the patient with the refluxing unit showed regression. Postoperatively post-void residual urine decreased by 89%, detrusor leak point pressure decreased significantly by a mean +/- SD of 66 +/- 18 vs 37 +/- 4 cm H(2)O and uroflowmetry showed a marked increase in maximum urine flow of 2 +/- 2 vs 17.8 +/- 8 ml per second. Three injections were needed in 1 patient to attain the desired response.
Urethral sphincter botulinum-A toxin injection could be considered a reliable treatment modality in children with nonneurogenic neurogenic bladder after the failure of conservative therapy.
我们评估了向非神经源性神经膀胱患儿的尿道尿道括约肌注射A型肉毒杆菌毒素(保妥适),以降低尿道阻力并改善排尿。在这些患者中,α受体阻滞剂药物治疗失败,注射是无法进行生物反馈治疗时的一种替代方法。
对10名6至17岁(平均年龄8岁)的非神经源性神经膀胱患儿进行了前瞻性治疗,使用A型肉毒杆菌毒素(保妥适)。术前,所有患儿均接受了超声、排尿性膀胱尿道造影、排泄性尿路造影、磁共振成像和尿动力学研究,包括压力流、肌电图和尿流率测定。1例患者有单侧G3反流,4例有双侧G1至G3肾积水。使用小儿硬式内窥镜和4Fr注射针,在3点、6点和9点位置向尿道外括约肌注射50至100 IU A型肉毒杆菌毒素。随访6至15个月。根据反应每月重复注射,最多注射3次。
注射A型肉毒杆菌毒素后,除1例患者外,所有患者均能自主排尿而无需导尿。未发生急性并发症。4例双侧肾积水患者和1例有反流单位的患者病情出现好转。术后排尿后残余尿量减少了89%,逼尿肌漏点压力显著降低,平均±标准差从66±18 cm H₂O降至37±4 cm H₂O,尿流率测定显示最大尿流率显著增加,从2±2 ml/秒增至17.8±8 ml/秒。1例患者需要注射3次才能达到预期反应。
在保守治疗失败后,尿道括约肌注射A型肉毒杆菌毒素可被视为非神经源性神经膀胱患儿的一种可靠治疗方式。